
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 16, 2026
Vera ownership filings report September positions from T. Rowe Price, Avoro and Deep Track
Nasdaq: $VERABiotechnology · Kidney diseaseU.S. product launchU.S. supplemental filing
VERA Stock Hub: Vera Therapeutics News, Trutakna and IgA Nephropathy
Vera has started selling Trutakna under its U.S. accelerated approval and reported $10.3 million in its first quarter of product sales for the September period. A two-year randomized trial showed slower kidney function decline, and Vera submitted the results to support traditional approval. The commercial test is whether early demand turns into sustained sales quickly enough to fund launch spending and development. November 5 results · ORIGIN 3 final analysis · Current U.S. Food and Drug Administration (FDA) label.
Full research report · PDF
Vera Therapeutics, Inc. ($VERA), research updated November 19, 2026
17 pages on Trutakna, ORIGIN 3, the first commercial quarter and financing. For personal use only: redistribution prohibited.
Next dated sector catalyst
November 30, 2026 · FDA target date for Vertex’s povetacicept
Vertex reported an FDA goal date of November 30 for its application for accelerated approval in IgA nephropathy. Vera submitted its own supplemental application for Trutakna on November 3 and expects potential traditional approval in mid-2027, subject to FDA review. Vertex’s November 2 update · Vera’s regulatory timetable.
Vera presented interim adult PIONEER results on October 24. In its November 5 Form 10-Q, Vera said it expected additional Phase 2 PIONEER results in the fourth quarter of 2026, without specifying a date. Its European filing target is the first quarter of 2027. Quarterly filing · Company milestones.
VERA stock at a glance
Chart analysis · JC
Technical chart analysis of $VERA with bull and bear scenarios on JC Just Charts.
Where Vera Therapeutics stands now
Vera is in the first year of its transition from trial sponsor to commercial operation. The September report shows product revenue for the first time alongside a much larger commercial cost base than a year earlier. The November supplemental application contains the two-year kidney function data. Quarterly filing · November release.
Two milestones will move on different timelines. Coverage and repeat dispensing will determine how quickly the U.S. launch converts into net sales. The FDA will separately decide whether the confirmatory evidence supports changing the approval and label. FDA indication · Launch and application update.
Constructive case
Trial evidence and early uptake support a durable U.S. launch, and access improves as regulators review the longer data.
Cautious case
Competing launches and payer limits keep product receipts below the cost of selling, manufacturing and ongoing clinical work.
Latest VERA news
Nov 16, 2026
Vera ownership filings report September positions from T. Rowe Price, Avoro and Deep Track
T. Rowe Price reported 3.8%, Avoro reported 7.82% and Deep Track reported 9.71% beneficial ownership. The three filings measure positions on September 30.
Nov 13, 2026
FDA approves Gazyva for adults with primary membranous nephropathy at risk
The approval changes the treatment landscape for a condition that Vera is studying separately in its Phase 2 PIONEER trial.
Nov 10, 2026
State Street reports 4.6% beneficial ownership of Vera’s Class A shares
State Street reported 3,301,893 shares as of September 30. Its previous filing reported a 5.8% position as of June 30.
Nov 6, 2026
Vera reports two types of equity awards for three new employees
The November 2 awards were 14,900 options and 7,450 restricted stock units. Their vesting terms differ from immediate issuance of common shares.
Nov 5, 2026
Vera reports its first Trutakna sales and an October Oxford draw
September-quarter net product sales were $10.277 million. Vera held $384.042 million in cash and securities at September 30 and drew $75 million in gross principal in October.
Nov 3, 2026
Vera submits supplemental application for traditional Trutakna approval
Vera disclosed the submission in its November 5 update. The company expects potential traditional approval around mid-2027. The existing U.S. approval was accelerated.
Catalyst calendar
- July 7, 2026 — FDA granted accelerated approval to Trutakna to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. FDA approval letter
- September 15, 2026 — Vera announced final top-line efficacy results in ORIGIN 3. Company disclosure filed with the SEC
- October 22, 2026 — The final ORIGIN 3 efficacy analysis was presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine. Final study publication
- October 22–23, 2026 — Final VISIONARY and interim RAINIER results published. Otsuka reported completing its supplemental application. VISIONARY final · RAINIER interim · Otsuka announcement
- October 24, 2026 — PIONEER interim results in adults presented at ASN Kidney Week. Conference abstract
- November 3, 2026 — Vera submitted a supplemental biologics license application (sBLA) for traditional FDA approval. Company disclosure
- November 5, 2026 — Vera filed its September-quarter results, including initial product sales, and reported the October loan draw. Form 10-Q
- November 6, 2026 — Vera announced equity inducement awards granted to three new employees on November 2. Company announcement
- November 10, 2026 — Guggenheim investor event and State Street ownership filing. Company event announcement · Schedule 13G
- November 13, 2026 — FDA action on Gazyva for primary membranous nephropathy. Drugs@FDA record
- November 16, 2026 — T. Rowe Price, Avoro and Deep Track filed updated ownership disclosures. Ownership filings
- November 30, 2026 — Target date for FDA action on Vertex’s povetacicept application. Competitor regulatory milestone
- Fourth quarter 2026 — Window Vera identified in its November 5 filing for additional PIONEER results. Company expectation
- December 31, 2026 — The availability window ends for the remaining $50 million of Oxford Term A. Credit agreement
- First quarter 2027 — Vera targets a European marketing application for atacicept in IgA nephropathy. Company target
- Mid-2027 — Vera’s timeline for potential traditional approval in the U.S. Company expectation
- Second half of 2027 — Vera plans an IgAN marketing application in Japan. Company planning slide
Evidence, launch and access
ORIGIN 3
The clinical trial separates the basis of accelerated approval from the follow-up supporting Vera’s supplemental application.
First commercial quarter
Early launch measures show sales, patient paperwork and working capital on different timelines.
Competing treatments
Other products and upcoming decisions shape the market into which Vera is launching.
Vera Therapeutics deep dive: the full analysis
The analysis follows the trial and FDA record into the first product sales, the competition for patient access and the funding needed to support the launch. The Merlintrader Research Library collects our dated biotech stock research reports.
01 Bull, base and bear cases
Vera is now selling a treatment before regulators have acted on its longer randomized evidence. The clinical outcome matters to the value of the treatment. The commercial outcome depends on access, the number of eligible patients treated and how much each course of treatment contributes after costs.
Bull case · early starts become repeat prescriptions
Nephrologists continue prescribing Trutakna for eligible patients, insurers establish workable coverage and patients repeat treatment. Quarterly net sales broaden across accounts as the launch moves beyond initial customer stocking. The FDA finds the two-year evidence sufficient to support traditional approval, with labeling that describes the relevant renal outcome. At the same time, product costs, royalties and distribution charges stay manageable as volume rises. If commercial cash receipts improve enough, Vera can fund more of its operations without having to rely entirely on further debt or equity. A timely European filing would add a new opportunity with a clearly identifiable near-term payment to the licensor.
Base case · a commercial ramp with separate regulatory and financing milestones
Access improves gradually. Trutakna grows from a modest starting base while providers and payers compare it with established supportive care and newer medicines. The U.S. supplemental application moves through review and the European plan requires a separate submission. Vera continues paying for launch infrastructure, inventory and studies. The August and November filings show how spending changed as commercial activity began. Product sales and collections need additional quarters before a pattern is clear. Specialty-channel inventory and reimbursement timing could cause quarter-to-quarter variation even if prescribing steadily expands.
Bear case · sales ramp slowly while cash commitments persist
Patient paperwork takes longer to become reimbursed dispensing, new competition limits access or treatment starts fail to convert into repeat use. Regulatory action comes later than the company expects, or the eventual label leaves less room for differentiation than clinicians anticipated. Inventory and license commitments still require funding. Commercial borrowing adds cash and brings a new interest burden, while some further credit depends on revenue or lender agreement. A slower launch therefore raises the importance of cash collection, purchase commitments and the next source of financing.
What would falsify this reading
Commercial conversion. Several reports with sustained growth in net product sales, reasonable collections and improving operating cash flow would reduce concern about the gap between first revenue and a durable business. A widening gap between patient start forms and repeat dispensing, significant receivable growth or costly gross-to-net deductions would strengthen the cautious case. More useful disclosure would show fills, persistence or access measures with enough detail to interpret changes over time. First-quarter launch metrics · Revenue recognition and cash flow.
Regulatory outcome. A traditional approval decision and the actual text of the label would resolve the uncertainty about the U.S. indication and confirmatory evidence. A formal request for more work or an altered review timeline would extend it. Accelerated approval letter · Supplemental filing disclosure.
Commercial financing. If growth in net product revenue and collections covers a rising share of inventory and operating costs, Vera may have more financing options. Drawing a new loan tranche would add cash and debt. An issuance of common shares would raise cash and dilute existing ownership. Liquidity and debt · Credit agreement.
02 What Vera Therapeutics does
Vera Therapeutics, Inc. is a Delaware commercial-stage biotechnology company headquartered in Brisbane, California. It reports a single Therapeutics segment and trades as VERA on Nasdaq. Its fiscal year ends December 31. Trutakna, the brand name for atacicept-vymj, became its first commercial product in the U.S. following accelerated approval in July 2026. Vera obtained worldwide rights to relevant patents and know-how through its agreement with Ares Trading S.A., an affiliate of Merck KGaA of Darmstadt, Germany. Paid milestones, ongoing royalties and contingent future obligations follow from that agreement. Form 10-Q, Notes 1, 5 and 12 · FDA product label.
Primary immunoglobulin A nephropathy, or IgAN, is a disease of the kidney’s filtering structures involving immune complexes containing IgA. Some patients progress through persistent injury to loss of kidney function. Protein in urine and the estimated glomerular filtration rate (eGFR) are distinct measures used to follow this course. In a U.K. registry cohort of 2,299 adults and 140 children, Pitcher et al., Clinical Journal of the American Society of Nephrology 2023, reported a relationship between time-averaged proteinuria and kidney outcomes. The cohort enrolled people meeting particular risk and diagnostic criteria. Its outcomes describe those participants and support investigation of markers of progression. Pitcher et al., CJASN 2023 · KDIGO guideline executive summary.
Atacicept blocks two signals associated with B-cell function, B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). This is intended to modify the immune process contributing to IgAN rather than address only a downstream consequence of kidney injury. The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 guidance distinguishes approaches directed at immune injury from those aimed at the consequences of nephron damage. Blood pressure control, therapy directed at the renin–angiotensin system and options that address kidney risk remain relevant to the setting in which new products are tested and used. The evidence for adding a therapy depends on the treatment population and background care in each trial. FDA description and approved use · Kidney International, KDIGO 2025.
Vera has other licensed programs and studies in kidney disease. Their near-term economics differ from Trutakna’s commercial sales. Early data can identify where to test next, but they create research spending before any potential return. Vera’s first product also changes the meaning of its expense base. Selling and administrative costs now include a commercial organization, while manufacturing and royalties enter reported cost of sales. Those changes make the year-over-year comparison useful for seeing how the launch changes the business. Segment disclosure and operating expenses.
03 FDA review, Europe and the next reported dates
The Food and Drug Administration approved Trutakna under the accelerated pathway on July 7, 2026. The U.S. indication covers reducing proteinuria in adults with primary IgAN at risk for disease progression. The label states that the long-term effect on kidney function decline had yet to be established under that approval and that continued approval may depend on verification of clinical benefit. The July approval letter requires a randomized confirmatory trial. Vera submitted the final ORIGIN 3 results to support conversion to traditional approval. Vera’s confirmation of the submission. FDA accelerated approval letter · Prescribing information.
Vera later aligned with the FDA on an earlier analysis of ORIGIN 3. It reported the final results in September and submitted its supplemental biologics license application on November 3. In its November 5 update, Vera expected possible traditional U.S. approval in mid-2027, subject to FDA review. Any FDA-assigned goal date for the supplement would be a separate milestone. The July action concerned the original application. Form 10-Q regulatory update · Submission and timing disclosure.
Vera also targets submission of a marketing authorization application in the European Union during the first quarter of 2027. A submission would start a separate process with the European authorities. It also matters to Vera’s balance sheet because the first filing under its Ares license triggers a $10 million payment. The application, review and commercial availability have distinct timelines. Even after an authorization, individual markets can have different procedures for price and reimbursement. Vera’s November presentation also targets a Japanese new drug application in the second half of 2027. That would be a separate submission. November catalyst schedule. European filing target · Ares license terms.
Vera presented interim adult PIONEER results on October 24. Separately, in its November 5 Form 10-Q, Vera said it expected additional Phase 2 PIONEER results in the fourth quarter of 2026, without specifying a date. In a different study, the ClinicalTrials.gov record for Phase 2 monthly atacicept records actual primary completion on September 22, 2026, and estimates overall completion in September 2027. PIONEER outlook · October presentation · Updated monthly study record.
04 ORIGIN 3 and the evidence after two years
Atacicept’s earlier evidence came from the randomly assigned Phase 2b ORIGIN study. Lafayette et al., Kidney International 2024, reported 116 participants with biopsy-proven IgAN and used the urine protein-to-creatinine ratio (UPCR) to evaluate change in proteinuria. Barratt et al., Journal of the American Society of Nephrology 2025, followed participants through an open-label extension. The extension reported sustained changes in UPCR and other markers, including an estimated mean annual eGFR slope of about −0.6 mL/min/1.73 m² through 96 weeks. People completing the blinded phase could enter the extension and receive atacicept. The extension adds follow-up, but it separates drug effect from other influences less cleanly than the randomized comparison. Lafayette et al., Kidney International 2024 · Barratt et al., JASN 2025.
In the first 203 patients evaluated for the prespecified interim Phase 3 analysis, the 36-week reduction in UPCR from baseline was 45.7% with atacicept and 6.8% with placebo. Lafayette et al., New England Journal of Medicine, published online in 2025, reported a 41.8% relative reduction in the geometric mean ratio versus placebo, with a 95% confidence interval of 28.9% to 52.3% and P<0.001. The published estimate compares ratios calculated under the analysis and differs from simply subtracting the two percentage decreases from baseline. Proteinuria was the surrogate endpoint supporting accelerated approval. Lafayette et al., NEJM, online 2025 · FDA’s clinical review.
The trial randomized 431 participants. The final efficacy analysis included 428 treated participants, 214 in each group. Barratt et al., New England Journal of Medicine 2026, reported a difference in change in eGFR from baseline at week 52 and a slower annualized decline over 104 weeks. The prespecified progression composite was also less frequent in the atacicept group. The composite aggregates kidney events of different kinds, so its hazard ratio applies to the defined combined outcome. It gives a different measure of benefit than a single event such as requiring dialysis. Barratt et al., NEJM 2026 final analysis · ORIGIN program registry.
| Outcome | Atacicept | Placebo |
|---|---|---|
| Week 52 eGFR change, mL/min/1.73 m² | −0.11 | −5.69 |
| Annualized eGFR slope through week 104, mL/min/1.73 m²/year | −0.60 | −5.60 |
| Prespecified composite disease progression, participants | 11 | 38 |
| Participants with serious adverse events | 7.0% | 15.4% |
The annualized slope difference was 5.00 mL/min/1.73 m² per year (95% confidence interval 3.55 to 6.45). The estimated hazard ratio for the composite was 0.24 (95% confidence interval 0.12 to 0.48). The trial reported 74.8% and 78.0% of participants with adverse events in the atacicept and placebo groups, respectively. The July FDA label uses its own safety window and includes precautions concerning infection and immunosuppression. It also reports local administration reactions in 30% of atacicept recipients and 5% of placebo recipients in that dataset. The trial and label rates describe defined observation periods and populations. Final efficacy and safety results · FDA safety information.
Through 104 weeks, Vera’s September release counted eight placebo recipients and no atacicept recipients in the category of dialysis lasting at least 30 days, transplant or death. The final count was seven versus zero. The November filing notes that the updated tally excluded one placebo recipient who received transient dialysis for acute kidney injury. The prespecified composite count and hazard ratio provide the cleaner basis for judging the published kidney progression result. The trial’s length, eligibility criteria and care allowed in its protocol matter when assessing how those outcomes could translate to a broader population. Final report · Form 10-Q explanatory note.
05 What Vera’s first launch figures measure
Vera reported $10.277 million of net product revenue for the quarter ended September 30. It also said in the November 5 release that there had been about 700 patient start forms to date. A start form records an initial step toward therapy. Vera recognizes revenue when it delivers product to a pharmacy or distributor, after estimating rebates and other deductions. Company launch disclosures · Revenue recognition in Note 2.
Vera sells through a limited distribution network. The September filing reports that two customers accounted for 76% and 18% of gross product revenue and gross receivables. These customers are in the distribution system. Their shares show concentration at the point where Vera recognizes sales and handles collections, rather than concentration among individual clinics or patients. Delivery timing, returns, rebates and other gross-to-net deductions influence how much reported revenue Vera ultimately collects. Comparison with later quarters can show whether customer concentration shifts as access broadens and whether inventory becomes available across more accounts. Concentration and sales deductions.
Net accounts receivable totaled $11.981 million and inventory was $7.078 million at September 30. Both balances were zero at year-end 2025 in the filed balance sheet. They show part of the working capital required by the launch. Receivables show amounts still to be collected as of a balance sheet date. Inventory is a supply asset whose useful level depends on demand, lead times and contract commitments. Both can rise during an orderly launch, and a sustained build outpacing sales would deserve closer scrutiny. Balance sheet and inventory policies.
The manufacturer’s revenue depends on recognized customer sales after allowances rather than the amount that a payer or patient may see at the point of care. That is especially important when assessing a specialty launch where payers can apply different coverage rules. Data on time to fill, repeat dispensing, coverage and product returns would help identify whether growth reflects broader access or timing of product shipments. Disclosures on customers, pricing and revenue.
06 Competition and the next IgAN decision
Vertex has an application for accelerated approval under FDA priority review for povetacicept, another medicine directed at BAFF and APRIL. Its November 2 results list November 30, 2026, as the FDA target action date. A favorable decision could give payers and nephrologists another option in the same therapeutic area while Vera seeks traditional approval for Trutakna. Vertex has also registered a Phase 3b study comparing device experience between povetacicept and sibeprenlimab. That comparison evaluates the administration experience defined in its protocol. It gives no basis for an efficacy ranking against Vera’s treatment. Vertex’s regulatory update · Registered Phase 3b device study.
In the prespecified RAINIER interim efficacy analysis of the first 199 randomized participants, 24-hour urinary protein-to-creatinine ratio fell 52.0% with povetacicept and 4.3% with placebo at week 36. The published analysis describes proteinuria and related endpoints at the earlier follow-up, while the study continues. The interim comparison supports Vertex’s accelerated-approval application. The separate drugs’ randomized studies each use their own patient populations, endpoints and follow-up. Barratt et al., NEJM 2026, RAINIER interim · Vertex regulatory update.
Otsuka’s Voyxact, or sibeprenlimab-szsi, received FDA accelerated approval for reducing proteinuria in adults with primary IgAN at risk for progression in November 2025. It selectively targets APRIL. Perkovic et al., New England Journal of Medicine, published online in 2025, reported the prespecified interim VISIONARY analysis. In the first 320 patients eligible for the nine-month analysis, sibeprenlimab reduced proteinuria compared with placebo. Rizk et al. reported the final analysis on October 22, 2026. At 24 months, annualized eGFR slope was +0.3 with sibeprenlimab and −4.2 with placebo, a difference of 4.5 mL/min/1.73 m² per year. On the same date Otsuka said it had completed a rolling supplemental application for traditional U.S. approval. FDA approval and interim trial summary · Perkovic et al., NEJM 2026, interim · Rizk et al., NEJM 2026, final · Otsuka regulatory update.
Fabhalta, or iptacopan, acts in the alternative complement pathway. Its July 2026 U.S. label includes slowing kidney function decline in adults with primary IgAN at risk for disease progression, following traditional approval for that use. Barratt et al.’s final 24-month APPLAUSE-IgAN analysis in the New England Journal of Medicine in 2026 reported an eGFR slope difference of 3.02 mL/min/1.73 m² per year in favor of iptacopan versus placebo. Regulatory review considers each treatment’s own trial, measured benefit and safety profile. Separate randomized comparisons with different enrollment and endpoints are insufficient to declare a winner. Updated Fabhalta label · Final APPLAUSE-IgAN publication.
Other FDA-approved IgAN therapies are already on the market. Tarpeyo is an oral delayed-release formulation of budesonide labeled to reduce kidney function loss in at-risk adults with primary IgAN. Filspari, or sparsentan, has a label to slow kidney function decline in the same disease and a separate indication in specified patients with focal segmental glomerulosclerosis. Vanrafia, or atrasentan, received accelerated approval in April 2025 to reduce proteinuria in adults with primary IgAN at risk of rapid progression. These treatments have their own indications and clinical evidence. Tarpeyo U.S. label · Filspari U.S. label · Vanrafia approval package.
The FDA also granted accelerated approval to ravulizumab-cwvz, marketed as Ultomiris, for an IgAN indication in October 2026. The approved alternatives differ in administration, regulatory endpoints and safety monitoring. In primary membranous nephropathy, another disease Vera is studying, the FDA approved Gazyva (obinutuzumab) in November to induce remission of proteinuria in adults at risk for disease progression. FDA ravulizumab approval letter · FDA membranous nephropathy announcement.
07 PIONEER and the rest of the pipeline
PIONEER is an open-label Phase 2 basket study. It evaluates atacicept across distinct glomerular diseases and includes adult cohorts with IgA nephropathy and primary membranous nephropathy, among others. At Kidney Week on October 24, Vera presented early adult results. The conference abstract included 94 adults in the IgAN cohort at the August cutoff, including 14 with IgA vasculitis nephritis and six with recurrence after transplant. Mean change in 24-hour UPCR from baseline was minus 34% at week 12 and minus 41% at week 24. The denominators depend on which participants had reached each visit by the cutoff. Kidney Week abstract · Registered study design · Vera’s presentation recap.
The August analysis also included ten adults with primary membranous nephropathy and antibodies against phospholipase A2 receptor (PLA2R). Mean anti-PLA2R levels declined by 63% from baseline at week four, and mean 24-hour UPCR declined by 32% at week 12. One of seven patients assessed against the week-four antibody threshold had a concentration below 14 relative units per milliliter. The antibody signal and change in urine protein are observations from a small study without a concurrent control. Longer follow-up would establish whether the initial changes persisted and give a clearer view of outcomes such as remission. Cohort and endpoint data · FDA decision in membranous nephropathy.
Vera’s November presentation reports a later dataset. Its IgAN chart lists 101 at baseline and 66 at week 24, when it shows a 52% geometric mean decline in 24-hour UPCR from baseline. The primary membranous nephropathy baseline table lists 16 adults. The associated charts show changes in antibody levels and urine protein with fewer observations at each follow-up visit. These are sponsor-reported findings from the same open-label study at a later snapshot. Differences from the August abstract can reflect both follow-up and the change in analysis populations and summaries. Vera’s planning slides show further PIONEER and ORIGIN EXTEND data in 2027 and 2028 without specific disclosure dates. November presentation, slides 25–27 and 33.
The PIONEER registry also includes focal segmental glomerulosclerosis and minimal change disease. A response in one disease leaves the expected benefit in the other unresolved, so those populations need individual assessments. The pediatric work presented at Kidney Week concerned study design. The adult Phase 3 results therefore remain the strongest quantitative evidence behind the current label. ORIGIN EXTEND offers atacicept to eligible participants who completed the protocol-defined treatment period in a parent atacicept study for IgA nephropathy. Its results can add experience over time, which is a different contribution from repeating the placebo-controlled comparison. Basket trial eligibility · Pediatric presentation · ORIGIN EXTEND.
The Phase 2 monthly schedule matters because fewer injections would change the practical burden of treatment. Its primary and overall completion milestones are separate. The approved regimen remains the weekly dose in the labeling. A future monthly regimen would need its own evidence on exposure, durability, response and safety, particularly near the end of each dosing interval. Vera also has VT-109, a preclinical program licensed from Stanford, and previously studied investigational MAU868 in kidney transplant recipients in Phase 2. The September filing assigns no product revenue to either. Monthly study protocol · Approved dosage · Other programs and license disclosures · MAU868 trial record.
08 Financial results and cash spent in operations
The quarter ended September 30, 2026, is the first reporting period with product sales. The $10.277 million revenue line is net product sales, with July approval preceding the first reported sales. Cost of goods sold was $3.296 million. Merlintrader calculation gives a $6.981 million gross profit and a 67.9% gross margin. Both belong to this early volume and cost mix. Vera previously expensed certain costs of manufacturing supply before regulatory approval. It estimates that reported cost of sales would have been about $0.4 million higher for the quarter had the previously expensed manufacturing costs been included when that inventory was sold. That timing difference matters when comparing future reported gross margins. Revenue, cost of goods sold and inventory accounting.
| USD millions, except per share | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Net product sales | 10.277 | 0 | 10.277 | 0 |
| Cost of goods sold | 3.296 | 0 | 3.296 | 0 |
| Research and development | 41.253 | 56.473 | 187.344 | 155.946 |
| Selling, general and administrative | 61.430 | 27.459 | 152.961 | 65.321 |
| Operating loss | (95.702) | (83.932) | (333.324) | (221.267) |
| Net loss | (93.711) | (80.293) | (324.216) | (208.518) |
| Loss per share, basic and diluted | (1.30) | (1.26) | (4.51) | (3.27) |
Source: September 2026 condensed consolidated statements of operations. Positive net interest income and the other nonoperating items explain why the net loss is smaller than the operating loss for the nine months through September. Clinical and manufacturing timing also explain why quarterly R&D fell year over year even as nine-month R&D increased. By contrast, the quarterly increase in selling, general and administrative costs reflects the organizational investment ahead of and during the launch. The commercial question is how much recurring expense stays in the base once the initial infrastructure is in place.
Cash used in operations was $305.929 million in the first nine months, versus $171.110 million in the comparable 2025 period. The June filing gave first-half amounts of $206.753 million and $109.204 million. Subtracting those amounts gives quarterly cash use of $99.176 million and $61.906 million respectively, a Merlintrader calculation. Sales recognized, cash collected, inventory consumed and costs incurred can move in different periods. Share-based compensation, at $44.799 million through September, is an example of an expense without equivalent immediate cash outflow. Cash collections from product customers and working capital determine when net sales improve the operating cash line. First-half cash flow statements · Nine-month cash flow statements.
Ares milestone payments of $15 million in January and $20 million in August appear as investing cash uses. The first was expensed in R&D upon FDA acceptance of the original application. The second followed accelerated approval, was capitalized and is amortized through cost of goods sold. Including both in a simple September year-to-date cash-use bridge, operating cash use plus the two milestones was $340.929 million, a Merlintrader calculation before purchases of software or equipment. The reported investing line also contains maturities and purchases of marketable securities, so its net total offsets transactions with very different economic purposes. Cash flow presentation and intangible assets note.
The December quarter, the first full quarter following the July launch, can help answer whether repeat dispensing is becoming a meaningful source of sales. Quarterly totals may include fulfillment through specialty distribution or timing differences in collections. A sustained improvement would show up across net product revenue, product receivables, operating use and eventually the relationship between gross profit and commercial spending. The launch’s early costs and a one-time milestone payment cannot be projected as a fixed future cash requirement. Revenue recognition and operating cash disclosures.
09 Liquidity, Oxford borrowing and commitments
At September 30 Vera held $55.322 million of cash and equivalents plus $328.720 million in marketable securities, or $384.042 million in total. This compares with about $499.2 million at June 30 and $714.589 million at the end of 2025. The change in those balances was a decrease of $115.119 million in the third quarter, a Merlintrader calculation. The securities are part of the liquidity picture. Transfers between securities and cash can raise the cash-only balance without creating additional liquidity. Vera’s November filing estimated funding for at least 12 months from issuance. Its liquidity discussion also refers to available borrowing in assessing the operating plan. September liquidity and Note 1 · June balance sheet.
Oxford principal was $75 million on September 30, with a $75.434 million carrying value and a 9.74% accounting effective interest rate. Vera drew another $75 million gross during October after the FDA approval made that tranche available. The company received $74.0 million net and disclosed $150 million in total principal on October 31. The two dates matter when reading the balance sheet. The $500 million contractual ceiling includes availability subject to future conditions. Debt note and subsequent borrowing · Oxford agreement.
| Term loan capacity after the October draw | Amount | Funding condition |
|---|---|---|
| Term A remainder | $50 million | Borrower discretion through December 31, 2026, subject to the agreement’s terms |
| Term C | Up to $50 million | At least $75 million in trailing six-month net product revenue, within contractual window |
| Term D | Up to $50 million | At least $150 million in trailing six-month net product revenue, within contractual window |
| Term E | Up to $200 million | Joint lender and borrower discretion |
The Term C deadline is the earlier of 120 days after the milestone and December 31, 2027. The equivalent Term D outside date is June 30, 2028. The cash rate is the higher of the one-month CME Term Secured Overnight Financing Rate (SOFR) and 3.75%, plus 4.95 percentage points, and the exit fee is 5% on the applicable principal. June 1, 2030 is the stated maturity, subject to a one-year extension if the specified trailing-year net product revenue is at least $400 million and has not declined year over year. A different rate environment changes interest payments, and principal repayment and the exit fee remain separate uses. Contractual interest, repayment and availability · Debt maturities and financial covenants.
Oxford holds security over substantially all assets, with exceptions including intellectual property subject to a negative pledge. Specified permitted royalty financing or convertible borrowing can trigger an intellectual-property lien. From March 31, 2027, the minimum liquidity requirement applies continuously. The contract provides two exemptions: a $1 billion or higher market capitalization at the end of each trading day, or aggregate term loan funding above $200 million. It calls for unrestricted cash and equivalents in specified accounts of at least 60% of then-outstanding principal before the defined approval and 35% after it. Where aggregate funding exceeds $200 million, a month-end loan coverage requirement of at least 1.00-to-1 replaces the liquidity test. The numerator is annualized six-month net product revenue plus unrestricted cash and equivalents in specified accounts, and the denominator is then-outstanding principal. The agreement exempts Vera from the coverage test above a $1.25 billion month-end market capitalization threshold. Exactly $1.25 billion does not qualify for this exemption. Eligible balances are held in specified U.S. collateral accounts under control agreements. The contract’s original approval condition is separate from the pending application for traditional approval. This creates a different constraint at higher borrowings: falling liquidity can reduce debt capacity just when financing would otherwise be attractive. Oxford agreement, covenants and definitions.
Vera reported $88.137 million of minimum purchases under two manufacturing agreements, with $38.901 million scheduled for the remainder of 2026 and $49.236 million for 2027. In October it also canceled certain research manufacturing activities. Vera expected to recognize a loss of up to $14.6 million in fourth-quarter research and development expense from those canceled activities. Product purchase schedules affect liquidity even while existing inventory is carried or dispensed. The R&D cancellation affects a different set of activities. Commitments and contingencies.
10 Share count, compensation and financing alternatives
Class A common shares outstanding were 71,267,429 at the end of 2025, 72,287,904 at September 30 and 72,298,770 as of October 29. The September balance included 332,019 shares issued during the quarter from option exercises, vested units and employee purchases. The outstanding count measures ownership at one moment. The 72,126,588 weighted average shares used for the third-quarter per-share loss reflect the time each share was outstanding during the reporting period. A per-share model needs the right count for its period and purpose. Cover page, equity statements and earnings per share.
At September 30, there were 9,726,290 options with a $24.52 weighted-average exercise price. Of those, 5,282,414 were exercisable at a weighted-average $17.57. There were also 2,245,765 unvested restricted stock units (RSUs) and 19,714 shares associated with employee stock purchases excluded from diluted earnings per share. The full excluded total was 11,991,769. Merlintrader calculation puts that count at roughly 16.6% of September common shares as a simple overhang comparison. Vesting, settlement, and exercises each come with different conditions. Vera reported a net loss, which produces antidilutive treatment under the per-share calculation. The filing’s schedule did not include an outstanding warrant category. Notes 7, 8 and 10.
An issuance under the August 2025 TD Cowen at-the-market (ATM) sales agreement would be a separate source of common shares. Vera disclosed no sales under the $200 million authorization through September 30, 2026. Cash raised and the share count actually issued would depend on transactions under the agreement. A prior December 2025 follow-on delivered about $281.3 million in net proceeds from 7,058,824 shares. That financing explains part of the opening liquidity and demonstrates prior access, while the terms of future financing depend on future conditions. An October loan draw affects leverage and interest expense without issuing common stock. Equity transactions and ATM disclosure · 2025 financing history.
On November 2 Vera granted 14,900 options with a $30.25 exercise price and 7,450 restricted stock units to three new employees, as disclosed on November 6. Those grants were new potential equity after the reporting date. They cannot be added to the October 29 outstanding common share balance as issued shares. More broadly, the option and unit pool creates separate paths to dilution from any future cash financing. An option can deliver exercise proceeds on settlement, while the units do not have the same exercise-price economics. November inducement grant announcement.
11 Institutional positions and reported insider transactions
November beneficial ownership filings update holdings measured on September 30. They use distinct reporting bases and can cover the same shares deemed attributable to multiple reporting persons in a filing. State Street filing · T. Rowe Price filing · Avoro filing · Deep Track filing.
| Filer | Filed | Class A beneficial ownership as of September 30, 2026 | Filed percentage |
|---|---|---|---|
| State Street | November 10 | 3,301,893 | 4.6% |
| T. Rowe Price Associates | November 16 | 2,753,148 | 3.8% |
| Avoro | November 16 | 5,635,000 | 7.82% |
| Deep Track | November 16 | 7,000,000 | 9.71% |
State Street’s June snapshot was 4,148,786 shares and 5.8%. Its reported September position of 4.6% was below the 5% reporting threshold. T. Rowe Price reported 4,573,684 shares and 6.4% as of March 31, and also reported a position below the threshold in its November filing. Avoro and Deep Track each list more than one reporting person for their respective blocks. Both used the 72,063,335 Class A shares outstanding on July 29 as the denominator for their percentages. State Street June position · T. Rowe Price March position · Avoro ownership basis · Deep Track ownership basis.
A September 17 Form 4 reported that Chief Executive Officer Marshall Fordyce exercised options for 18,500 shares and sold 18,500 shares on September 15. The filing attributes the sales to a Rule 10b5-1 plan. The filing reported direct holdings of 235,244 common shares after that transaction. A September 14 filing by chief accounting officer Joseph Young reported an option exercise for 5,000 shares on September 11 and direct holdings of 80,754 shares afterward. The SEC’s code M covers an exercise or conversion of a derivative security exempt under Rule 16b-3. Both transactions described here were option exercises. A Form 144 is a separate notice of a proposed resale, such as Fordyce’s September 2 notice covering 64,750 shares, and gives no evidence by itself that the full proposed quantity traded that day. Fordyce Form 4 · Young Form 4 · September 2 Form 144 · SEC transaction codes.
12 Short interest and trading liquidity
Nasdaq reported 12,141,556 shares short at the October 30 settlement date, down from 13,587,185 on October 15. Average daily volume in the corresponding snapshots fell from 1,895,769 to 1,433,704 shares. Days to cover therefore rose from 7.167 to 8.469 even though the number of short shares fell. The two measures describe different aspects of positioning. The first counts shares still short at settlement. The second adjusts that inventory for the stock’s observed average trading volume over the reporting period. Nasdaq VERA short interest · FINRA short interest reporting.
The October 15-to-October 30 difference was 1,445,629 short shares, or about 10.6%, a Merlintrader calculation. Two settlement observations provide limited evidence about changes on any individual day. Daily short-sale volume measures transactions, and a short sale can be closed before the reporting date. For assessing liquidity around the next operating or regulatory milestone, volumes and days to cover can help frame how concentrated positioning is relative to typical trading activity. They do not determine the direction of trading after a decision. Settlement dates and volume columns · Reporting methodology.
A ratio using October 29 Class A shares outstanding would measure shares sold short against all outstanding shares. A percent-of-float measure uses an estimate of the tradable share count. Reported Class A outstanding shares · Published short interest series.
13 License economics, risks and valuation inputs
Vera licenses atacicept from Ares Trading, an affiliate of Merck KGaA. The filing lists a $10 million milestone upon the first filing of an EU approval application, up to $131.5 million in other regulatory milestones and up to $515 million in commercial milestones. Commercial milestones begin with $15 million at $250 million in annual worldwide net sales and $50 million at $500 million. The agreement carries tiered royalties from the low double digits to the mid-teens on annual worldwide net sales. Royalty expense enters cost of goods sold. The first European filing milestone matters before a European commercialization decision, while the sales thresholds require specified performance. Ares license, Note 5 and risk factors.
Revenue scenarios should use the eligible treated population, time to begin therapy, duration on therapy and net revenue per patient after allowances. Those inputs can diverge materially from eligible diagnosis counts. Vera’s initial gross margin includes royalties and amortization of acquired intellectual property. Manufacturing cost effects can change as earlier expensed inventory is consumed. Future milestone payments should be assigned to the periods or probability cases in which the contract triggers them. Net product revenue policy, cost of goods and milestone disclosures.
For a cash-flow approach, the timing of revenues should be paired with clinical spending, commercial investment, manufacturing commitments and funded debt service. The effect of different patient persistence assumptions grows with time. A patient who does not remain on therapy contributes fewer patient-months and the commercial costs dedicated to onboarding that patient may already have been incurred. From the equity perspective, the effect of leverage and potential issuance changes as the business moves toward or away from operating cash self-sufficiency. An attractive patient opportunity and an attractive outcome per share can require different sets of assumptions.
Geographic growth likewise combines multiple decisions. A European application is distinct from an authorization, and authorization is distinct from effective access in national markets. Higher net sales can trigger both the Ares payments and access to additional Oxford financing. The contractual bases differ across those arrangements. Merlintrader reading: an upside scenario is more persuasive when the business can absorb the additional obligations out of operating inflows. A more cautious scenario uses slower commercial growth and tests how much financing flexibility remains with weaker operating liquidity. Contractual exposure and funding discussion · Loan availability tests.
Merlintrader Health Score · $VERA
3.20out of 5
Assessed November 19, 2026. Merlintrader calculation: 3.0 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 3.0 × 10% = 3.20 out of 5. The score assesses financial and operating robustness over the next 12 to 18 months. It is not a rating, a target price or an indication to buy or sell.
Red flags
- The U.S. label rests on accelerated approval. Traditional approval requires FDA action on Vera’s supplement.
- The first sales quarter gives limited evidence on refill persistence and net price after payer allowances.
- A changing treatment market can influence access. Vertex’s November 30 date belongs to a competing application.
- Planned spending and manufacturing commitments compete for existing liquidity. Most residual Oxford capacity has conditions.
- Share-based compensation and equity financing could increase the common share count.
VERA Stock FAQ: Vera Therapeutics Questions Answered
Has the FDA approved Vera Therapeutics’ Trutakna?
The FDA granted accelerated approval to Trutakna on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Traditional approval is the subject of a later supplemental application. FDA approval letter · Prescribing information.
How much cash and marketable securities did Vera Therapeutics report?
Vera reported $384.042 million in cash, cash equivalents and marketable securities as of September 30, 2026. The balance comprises $55.322 million in cash and equivalents and $328.720 million in securities. The Oxford draw happened in October. Balance sheet and debt note.
How many Vera Therapeutics common shares were outstanding?
Vera reported 72,298,770 Class A common shares outstanding on October 29, 2026. The company had 72,287,904 Class A shares outstanding at the September 30 quarter end, with options and unvested restricted units disclosed separately. Cover and equity note.
What were Vera Therapeutics’ third-quarter 2026 financial results?
Vera reported $10.277 million in net product sales and a $93.711 million net loss for the quarter ended September 30, 2026. It was the first quarter with product sales, and basic and diluted loss per share was $1.30. Quarterly financial statements.
What does Vera Therapeutics do?
In its November 5, 2026, quarterly filing, Vera said it develops and sells treatments for serious immunological diseases. Its first marketed product, Trutakna, is approved to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Business overview · FDA label.
What is the next dated sector catalyst for Vera Therapeutics?
Vertex said on November 2, 2026, that November 30, 2026, is the FDA goal date for its povetacicept application for accelerated approval in IgA nephropathy. This is a competitive milestone for Vera, whose Trutakna already has accelerated U.S. approval. Vertex quarterly update · FDA’s Trutakna approval.
When could the FDA grant traditional approval for Vera Therapeutics’ Trutakna?
On November 5, 2026, Vera said it expected potential traditional U.S. approval in mid-2027, subject to FDA review. It submitted its supplemental application on November 3, 2026. Vera’s November 5 update.
Sources
- Vera Therapeutics filings and disclosures: September Form 10-Q, June Form 10-Q, 2025 Form 10-K, November 5 results, Oxford credit agreement and November corporate presentation.
- FDA: Trutakna decision, prescribing information, integrated review, Fabhalta label, Tarpeyo label, Filspari label, Vanrafia approval, Voyxact review summary, Ultomiris approval letter and Gazyva in membranous nephropathy.
- Atacicept clinical publications: Lafayette et al., NEJM 2026, ORIGIN 3 interim, Barratt et al., NEJM 2026, final analysis, Lafayette et al., Kidney International 2024, ORIGIN Phase 2b and Barratt et al., JASN 2025, extension.
- IgA nephropathy literature: Pitcher et al., CJASN 2023, RaDaR, Floege et al., Kidney International 2025, KDIGO executive summary, Barratt et al., NEJM 2026, APPLAUSE-IgAN final, Perkovic et al., NEJM 2026, VISIONARY interim, Rizk et al., NEJM 2026, VISIONARY final and Barratt et al., NEJM 2026, RAINIER interim.
- Trial records and abstracts: ORIGIN 3, ORIGIN EXTEND, PIONEER, Kidney Week 2026, monthly dosing, MAU868 and Vertex device comparison.
- Ownership and trading: State Street, T. Rowe Price, Avoro, Deep Track, CEO Form 4, chief accounting officer Form 4 and Nasdaq short interest.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $VERA or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Biotechnology and pharmaceutical companies carry clinical, regulatory, commercial and financing risk, including dilution, and readers can lose capital. Readers are responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



